Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
By T. Hosaka, F. Suzuki, M. Kobayashi, Yuya Seko, Y. Kawamura, H. Sezaki, N. Akuta, Yoshiyuki Suzuki, S. Saitoh, Y. Arase and 3 more. Hepatology, 2013
683 citations recorded by the source corpus.
Chronic hepatitis B virus (HBV) infection leads to cirrhosis and hepatocellular carcinoma (HCC). Antiviral agents are thought to reduce HCC development, but agents such as lamivudine (LAM) have a high rate of drug resistance. We compared the incidence of HCC in 472 entecavir (ETV)‐treated patients and 1,143 nontreated HBV patients (control group). Propensity score matching eliminated the baseline differences, resulting in a sample size of 316 patients per cohort. The drug mutation resistance was 0.8% (4/472) in the ETV group. The cumulative HCC incidence rates at 5 years were 3.7% and 13.7% for the ETV and control groups, respectively (P < 0.001). Cox proportional hazard regression analysis, adjusted for a number of known HCC risk factors, showed that patients in the ETV group were less likely to develop HCC than those in the control group (hazard ratio: 0.37; 95% confidence interval: 0.15‐0.91; P = 0.030). Both cohorts were applied in three previously reported risk scales and risk scores were generated based on age, gender, cirrhosis status, levels of alanine aminotransferase, hepatitis B e antigen, baseline HBV DNA, albumin, and bilirubin. The greatest HCC risk reduction occurred in high‐risk patients who scored higher on respective risk scales. In sub analyses, we compared treatment effect between nucleos(t)ide analogs, which included matched LAM‐treated patients without rescue therapy (n = 182). We found HCC suppression effect greater in ETV‐treated (P < 0.001) than nonrescued LAM‐treated (P = 0.019) cirrhosis patients when they were compared with the control group. Conclusion: Long‐term ETV treatment may reduce the incidence of HCC in HBV‐infected patients. The treatment effect was greater in patients at higher risk of HCC. (HEPATOLOGY 2013)
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/d7f3a13ca1cd591a2069c709f3eac7974bd6fb9a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “cumulative incidence of HCC of 7 and 20%, respectively [133].”
- Molecular Biology of Hepatitis B Virus Infection (2015, neutral): “Following the current treatment guidelines, it has been found that therapy reduces short-term risk (e.g., five year) of HCC several fold (Hosaka et al., 2013).”
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, result): “Long-term cohort studies among entecavir-treated patients compared with historic untreated controls in Japan and Hong Kong demonstrated reduction in mortality, liverrelated complication and HCC, especially among patients with liver cirrhosis [210–212].”
- Hepatocellular carcinoma: a review (2016, background): “7%, with the greatest reduction occurring in cirrhotic patients.(10) The use of HBV vaccination has resulted in significant declines in the incidence of HCC from HBV.”